Business
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include:
About this update from Evofem Biosciences, Inc.
[{"type":"text","content":"-- 2024 Net Sales Increased 6% to $19.4 Million --","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"-- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense --","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"-- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch --","length":162,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include:","length":221,"tagName":"p"},{"type":"image","alt":"Women's health innovator Evofem Biosciences (OTCQB: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Women's health innovator Evofem Biosciences (OTCQB: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/b0b393f2cbffee7b6c52a7dea7c44bd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s3aOPVcdo91_a65mo20iIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b0b393f2cbffee7b6c52a7dea7c44bd2","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/780907/Evofem_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"list","items":[{"val":[{"type":"text","content":"Delivered $19.4 million of net sales in 2024, a 6% increase compared to 2023, despite ongoing fiscal constraints.","length":113,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":113,"olType":false},{"type":"text","content":"1) The vast majority of 2024 net sales were contributed by PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, Evofem's hormone-free, on demand contraceptive.2) The Company diversified its revenue stream with the July 2024 acquisition of SOLOSEC® (secnidazole) 2g oral granules, the single-dose oral treatment for bacterial vaginosis and trichomoniasis. Evofem relaunched SOLOSEC in November 2024 through its dedicated U.S. women's health commercial team.","length":496,"t...